drugset / Trial / NCT01795768
Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the activity of the FGFR inhibitor AZD4547 in patients with FGFR1 or FGFR2 amplified breast, squamous lung and stomach cancer whose cancers have progressed following previous chemotherapy
Timeline
- Start
- 2012-09
- Primary completion
- 2014-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fexagratinib | Small molecule | 80 mg | — |